Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chemomab Therapeutics Ltd. - American Depositary Shares (NQ:CMMB)

1.130 +0.030 (+2.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 98,412
Open 1.130
Bid (Size) 1.100 (7)
Ask (Size) 1.160 (11)
Prev. Close 1.100
Today's Range 1.070 - 1.140
52wk Range 0.5790 - 2.550
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease
Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers. 
Via Benzinga
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
From Chemomab Therapeutics
Via GlobeNewswire

Performance

YTD
-46.9%
-46.9%
1 Month
-30.2%
-30.2%
3 Month
-44.1%
-44.1%
6 Month
-28.0%
-28.0%
1 Year
+46.5%
+46.5%

More News

Read More
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
From Chemomab Therapeutics
Via GlobeNewswire
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Earnings Scheduled For November 14, 2024
Via Benzinga
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
From Chemomab Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics to Present at October 2024 Investor Conferences
From Chemomab Therapeutics
Via GlobeNewswire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Chemomab Therapeutics to Present at September 2024 Investor Conferences
From Chemomab Therapeutics
Via GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
Via InvestorPlace
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
Via Benzinga
Chemomab Therapeutics Announces $10 Million Private Placement
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Chemomab Therapeutics Ltd. - American Depositary Shares publicly traded?
Yes, Chemomab Therapeutics Ltd. - American Depositary Shares is publicly traded.
What exchange does Chemomab Therapeutics Ltd. - American Depositary Shares trade on?
Chemomab Therapeutics Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Chemomab Therapeutics Ltd. - American Depositary Shares?
The ticker symbol for Chemomab Therapeutics Ltd. - American Depositary Shares is CMMB on the Nasdaq Stock Market
What is the current price of Chemomab Therapeutics Ltd. - American Depositary Shares?
The current price of Chemomab Therapeutics Ltd. - American Depositary Shares is 1.130
When was Chemomab Therapeutics Ltd. - American Depositary Shares last traded?
The last trade of Chemomab Therapeutics Ltd. - American Depositary Shares was at 03/28/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.